Table 3.
ccfHPVpos primary surgery a (n = 4) | ccfHPVneg primary surgery a (n = 46) | ccfHPVpos primary surgery + adj b (n = 8) | ccfHPVneg primary surgery + adj b (n = 14) | ccfHPVpos primary oncology c (n = 54) | ccfHPVneg primary oncology c (n = 13) | P‐value d | |
---|---|---|---|---|---|---|---|
Histology | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | 1.00 e |
SCC | 3 (75.0) | 26 (56.5) | 7 (87.5) | 8 (57.1) | 50 (92.6) | 12 (92.3) | |
AC | 1 (25.0) | 15 (32.6) | 0 (0.0) | 5 (35.7) | 4 (7.4) | 1 (7.7) | |
ASC | 0 (0.0) | 5 (10.9) | 1 (12.5) | 1 (7.1) | 0 (0.0) | 0 (0.0) | |
HPV genotype f | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | 0.26 g |
HPV16 | 3 (75.0) | 20 (43.5) | 4 (50.0) | 3 (21.4) | 32 (59.3) | 5 (38.5) | |
HPV18 | 0 (0.0) | 11 (23.9) | 0 (0.0) | 5 (35.7) | 5 (9.3) | 1 (7.7) | |
HPV31 | 0 (0.0) | 2 (4.3) | 0 (0.0) | 1 (7.1) | 3 (5.6) | 1 (7.7) | |
HPV33 | 0 (0.0) | 1 (2.2) | 1 (12.5) | 1 (7.1) | 3 (5.6) | 1 (7.7) | |
HPV45 | 1 (25.0) | 4 (8.7) | 1 (12.5) | 1 (7.1) | 4 (9.3) | 3 (23.1) | |
Other | 0 (0.0) | 3 (6.5) | 1 (12.5) | 2 (14.3) | 4 (9.3) | 0 (0.0) | |
Multiple | 0 (0.0) | 5 (10.9) | 1 (12.5) | 1 (7.1) | 3 (5.6) | 2 (15.4) | |
Tumor size (mm) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | 0.61 h |
< 20 | 1 (25.0) | 32 (69.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
≥ 20 < 30 | 2 (50.0) | 11 (23.9) | 6 (75.0) | 9 (64.3) | 2 (3.7) | 0 (0.0) | |
≥ 30 < 40 | 0 (0.0) | 2 (4.3) | 2 (25.0) | 3 (21.4) | 8 (14.8) | 4 (30.7) | |
≥ 40 | 1 (25.0) | 1 (2.2) | 0 (0.0) | 2 (14.3) | 4 (7.4) | 9 (69.2) | |
Mean ± SD | 24.75 ± 11.3 | 17.3 ± 8.6 | 22.9 ± 6.6 | 28.6 ± 7.9 | 53.6 ± 19.2 | 49.9 ± 22.5 | |
Median (IQR) | 22 (7.75) | 14.5 (11.5) | 22 (5.25) | 25 (10.5) | 50.0 (22.3) | 40.0 (24.0) | |
FIGO 2018 i | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | 0.64 j |
IA1 | 0 (0.0) | 1 (2.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
IA2 | 0 (0.0) | 15 (32.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
IB1 | 1 (25.0) | 15 (32.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
IB2 | 2 (50.0) | 14 (30.4) | 3 (37.5) | 6 (42.9) | 0 (0.0) | 0 (0.0) | |
IB3 | 1 (25.0) | 1 (2.2) | 0 (0.0) | 1 (7.1) | 2 (3.7) | 1 (7.7) | |
IIA1 | 0 (0.0) | 0 (0.0) | 1 (12.5) | 1 (7.1) | 0 (0.0) | 0 (0.0) | |
IIB | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 21 (38.9) | 5 (38.5) | |
IIIB | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (18.5) | 0 (0.0) | |
IIIC1 | 0 (0.0) | 0 (0.0) | 3 (37.5) | 6 (42.9) | 26 (48.1) | 6 (46.2) | |
IIIC2 | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 3 (5.6) | 0 (0.0) | |
IVA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.9) | 1 (7.7) |
ccfHPVpos/neg patients referred for primary surgery, that is, primary surgery subgroup.
ccfHPVpos/neg patients referred for primary surgery and adjuvant oncological therapy, that is, primary surgery + adjuvant oncology subgroup.
ccfHPVpos/neg referred for primary oncological therapy, that is, primary oncology subgroup.
Statistical analyses were performed for the ccfHPVpos primary oncology subgroup vs. the ccfHPVneg primary oncology subgroup.
Fisher's exact test comparing SCCs vs. AC/ASCs.
HPV genotype according to analyses with the NGS HPV genotyping panel.
Fisher's exact test comparing HPV18/45 vs. all other HPV genotyping results.
Two‐sample t‐test with unequal variance.
Disease stage according to FIGO 2018 [2]. For patients having been re‐staged after surgery, the re‐staged stage is the one listed.
Fisher's exact test.